Skip to main navigation Skip to search Skip to main content

New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis

  • Michael Maher

Press/Media

Period19 May 2024

Media coverage

11

Media coverage